Spectrum Pharmaceuticals — Proxy Contest (June 2017)
10 slides from Spectrum Pharmaceuticals's proxy contest presentation, Jun 7, 2017
Slide 1: Spectrum Pharmaceuticals June 2017
Spectrum Pharmaceuticals June 2017
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current b
Slide 3: Spectrum is a Biotech Company Focused on Bringing Cancer Treatments to Patients in Need
Spectrum currently markets six oncology/hematology products that target rare types of cancer such as advanced metastatic colorectal cancer, acute lymphoblastic leukemia, multiple myeloma and non-Hodgkin’s lymphoma Spectrum is also in advanced stages of development with three new compounds ROLO
Slide 4: Spectrum has Been Successful at Acquiring and Advancing Drugs to Treat Cancer
4 Spectrum has Been Successful at Acquiring and Advancing Drugs to Treat Cancer 2012 • Acquired Ex-U.S. rights to market Zevalin • In-licensed ROLONTIS • Acquired Allos Therapeutics 2013 • Re-acquired rights for Qapzola from Allergan • In-licensed Evomela • Acquired Talon Therapeutics • Filed Beleod
Slide 5: Committed to Sound Corporate Governance
All directors elected annually Continuing changes to Governance Practices o Elected an independent Lead Director (Gino Lenaz) o Adopted Corporate Governance Guidelines o Adopted Stock Ownership Policy o Adopted Anti-Hedging Policy o Amended our 2009 Incentive Award Plan to prohibit recycling or
Slide 6: Long Term Incentive Compensation Program Revamped in 2017
6 Long Term Incentive Compensation Program Revamped in 2017 • In 2016, the Compensation Committee undertook a comprehensive review of the Company’s executive compensation practices • The new program was designed based on, benchmarking versus peers, feedback from shareholders, advice from an independ
Slide 7: 2016 Peer Group
7 2016 Peer Group AMAG Pharmaceuticals, Inc. Albany Molecular Research Inc. Genomic Health Inc. Luminex Corporation Amphastar Pharmaceuticals, Inc. Mimedx Group, Inc. Pernix Therapeutics Holdings, Inc. SciClone Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc. Halozyme Therapeutics, Inc. Sucampo P
Slide 8: Compensation Plan Structure
8 Compensation Plan Structure Base Salary • To attract and retain talent in a highly competitive labor market • Based on pay levels of comparable positions within peer group, as well as qualifications, experience and role characteristics • Merit increases based on individual performance and size of
Slide 9: CEO Compensation Overview
CEO Compensation Overview a Realized Pay
Slide 10: We Seek Your Support at Our Annual Meeting
10 We Seek Your Support at Our Annual Meeting 2016 Spectrum Pharmaceuticals Management Recommendations FOR Election of Directors FOR Advisory vote to approve the compensation of our named executive officers FOR every three years to conduct an advisory vote to approve the compensation of our na